Isolated, interstitial deletion of chromosome 5q in patients with MDS is associated with a clinical phenotype, termed the 5q-syndrome, that is characterized by a severe macrocytic anemia, a normal or elevated platelet count with hypolobated micromegakaryocytes and a low rate of progression to acute myelogenous leukemia [1] [2] [3] . The severe macrocytic anemia in del(5q) MDS patients has been linked to haploinsufficiency of RPS14 (ref. 4). In a screen for genes in the chromosome 5q33 common-deleted region associated with the 5q-syndrome, only small hairpin RNAs (shRNAs) targeting the RPS14 gene caused a severe block in erythroid differentiation, whereas forced overexpression of RPS14 in cells from MDS patients with the 5q deletion rescued erythropoeisis 4 .
Isolated, interstitial deletion of chromosome 5q in patients with MDS is associated with a clinical phenotype, termed the 5q-syndrome, that is characterized by a severe macrocytic anemia, a normal or elevated platelet count with hypolobated micromegakaryocytes and a low rate of progression to acute myelogenous leukemia [1] [2] [3] . The severe macrocytic anemia in del(5q) MDS patients has been linked to haploinsufficiency of RPS14 (ref. 4 ). In a screen for genes in the chromosome 5q33 common-deleted region associated with the 5q-syndrome, only small hairpin RNAs (shRNAs) targeting the RPS14 gene caused a severe block in erythroid differentiation, whereas forced overexpression of RPS14 in cells from MDS patients with the 5q deletion rescued erythropoeisis 4 .
Germline, heterozygous inactivating mutations or deletions of RPS19 and other ribosomal protein genes cause Diamond-Blackfan anemia (DBA), a disorder that, like del(5q) MDS, is characterized by macrocytic anemia [5] [6] [7] [8] [9] . Ribosomal dysfunction is sensed by the p53 pathway, leading to apoptosis and cell cycle arrest. Decreased expression of individual ribosomal proteins, including that of RPS19 and RPS14, increases p53 protein levels and p53 target-gene expression in cell lines, primary human hematopoietic progenitor cells and patient samples [10] [11] [12] . Pharmacologic or genetic inactivation of p53 rescues the differentiation defect in cells with ribosomal haploinsufficiency in multiple model systems 7, 8, 10, 13 .
Several in vivo models of ribosome dysfunction have been described 14 . A mouse model with a hematopoietic-specific, heterozygous deletion of Rps6 recapitulates the erythroid phenotype of del(5q) MDS and DBA, and this phenotype is rescued by p53 inactivation 7, 8, 15 ; however, RPS6 inactivation has not been described in either DBA or MDS. To model del(5q) MDS in mice, a series of DNA segments syntenic to the commonly deleted region on human chromosome 5, including those containing Rps14, was conditionally deleted from the HSC compartment 13 . Heterozygous loss of this region resulted in a macrocytic anemia and dysplastic megakaryocytes, recapitulating aspects of the 5q-syndrome. The smallest deletion tested that resulted in the erythroid defect included Rps14 and seven other genes.
To investigate the hematologic phenotype and molecular consequences specific to Rps14 haploinsufficiency in vivo and to explore the role of this gene in del(5q) MDS, we generated a mouse model with conditional Rps14 inactivation.
RESULTS

Rps14 haploinsufficiency induces a p53-dependent erythroid differentiation defect in late-stage erythroblasts
We generated a conditional Rps14-knockout model in which exons 2-4 are flanked by loxP sites (floxed Rps14, or Rps14 fl/fl , mice) ( Supplementary Fig. 1a ). After crossing these mice to Mx1-Cre + transgenic mice, in which the Cre recombinase is under the control of the hematopoietic cell-specific Mx1 promoter, we induced Rps14 excision in hematopoietic cells by treatment of 6-to 8-week-old mice with polyinosinic-polycytidylic acid (poly(I:C)) and confirmed haploinsufficient expression (approximately 50% of normal levels) of Rps14 (Supplementary Fig. 1b,c) . Mice with heterozygous deletion of Rps14 in hematopoietic cells (hereafter referred to as Rps14-haploinsufficient mice) developed a progressive anemia ( Fig. 1a and Supplementary Fig. 1d,e) . At approximately 550 d of age, the reticulocyte count of Rps14-haploinsufficient mice decreased precipitously and was associated with death in a subset of these mice (Fig. 1a,b) .
We next determined whether Rps14 haploinsufficiency causes a discrete, stage-specific defect in erythroid development. We characterized the stages of erythropoiesis by flow cytometry on the basis of the expression of Ter119 (also called lymphocyte antigen 76; Ly76) and CD71 (also known as transferrin receptor protein 1; TfR1) (which we refer to as RI, RII, RIII and RIV; Supplementary Fig. 1d ). At 18 months of age, Rps14-haploinsufficient mice had impaired erythropoiesis at the transition from CD71 + Ter119 + basophilic and early chromatophilic erythroblasts (the RII stage) to CD71 intermediate Ter119 + polychromatophilic (RIII) to CD71 low Ter119 + orthochromatophilic erythroblasts and enucleated erythrocytes (RIV) (Fig. 1c) . Moreover, Rps14-haploinsufficient mice had significant splenomegaly due to expansion of the early-erythroid compartment ( Fig. 1d and Supplementary Fig. 1i ). Younger mice, 22 weeks after excision of the floxed Rps14 allele, also had impaired differentiation at the RIII-RIV transition (P < 0.001) with a decrease in the quiescence of cells in the RI population (P < 0.001) (Supplementary Fig. 1f,g ). These results suggest that a compensatory increase in erythropoiesis occurs in young Rps14-haploinsufficient mice, causing a delay in the development of severe anemia. To determine whether Rps14 haploinsufficiency in hematopoietic cells but not bone marrow stroma drives anemia, we generated mixed-bone marrow chimeras (Supplementary Fig. 1h ). Wild-type (WT) mice transplanted with Rps14-haploinsufficient hematopoietic cells developed anemia with kinetics similar to that of untransplanted mice (compare Supplementary Fig. 1h to Fig. 1a) , confirming that the phenotype is caused by excision of Rps14 in hematopoietic cells.
We next examined the effect of Rps14 haploinsufficiency on stressinduced erythropoiesis, using mice in which hemolysis was induced by phenylhydrazine treatment. After acute hemolytic stress, Rps14-haploinsufficient mice developed more severe anemia and had a delayed reticulocyte response, as compared to Mx1-Cre control mice (Fig. 1e) . The RI population (CD71 + Ter119 − ) was significantly (P < 0.001) increased in frequency in Rps14 −/+ Mx1-Cre + mice, whereas the RIV population (CD71 low Ter119 high ) was significantly (P < 0.001) decreased in frequency, highlighting a terminal erythroid differentiation defect consistent with 
Rps14
-/+ Mx1-Cre Fig. 1j ). Rps14 −/+ Mx1-Cre + mice were characterized by significant splenomegaly with effacement of the normal spleen architecture and expansion of the red pulp (P < 0.05; Supplementary Fig. 1i ).
To analyze the effect of Rps14 haploinsufficiency on erythroid differentiation in the absence of in vivo compensatory mechanisms, we analyzed erythroid differentiation of lineage-negative hematopoietic stem and progenitor cells (HSPC) in vitro. After 5 d of culture, Mx1-Cre + HSPCs differentiated into hemoglobinized CD71 − Ter119 + cells, whereas Rps14-haploinsufficient cells did not terminally differentiate (Fig. 1f,g ). This terminal differentiation defect was accompanied by induction of the expression of Cdkn1a, which encodes the p53 downstream-target p21 (Fig. 1h) .
The p53 pathway is activated by decreased expression of ribosomal protein genes and has been linked to the erythroid defect in other models of ribosome dysfunction 7, 8, 10, 13 . We found that compound haploinsufficiency for Trp53 and Rps14 prevented mortality from high-dose phenylhydrazine treatment (35 mg per kg body weight (mg/kg); Fig. 1i ). After treatment with a lower dose (25 mg/kg), compound haploinsufficiency for Trp53 normalized the effects on erythropoietic recovery and spleen size caused by Rps14 haploinsufficiency ( Fig. 1j and Supplementary Fig. 1k,l) . In aggregate, these results demonstrate that Rps14 haploinsufficiency causes a Trp53-dependent terminal erythroid differentiation defect.
Rps14 haploinsufficiency affects hematopoietic stem and progenitor cells
We next evaluated whether Rps14 haploinsufficiency affects hematopoiesis more broadly. In a histopathological analysis of the bone marrow, we found that 18-month-old Rps14-haploinsufficient mice had a slightly decreased cellularity, diffuse hemosiderin deposition and substantially increased numbers of hypolobulated micromegakaryocytes, consistent with the pathognomonic cell morphology of bone marrow biopsies from individuals with del(5q) MDS ( Fig. 2a and Supplementary Fig. 2a,b) . Rps14-haploinsufficient mice had a mild thrombocytosis and platelet dysplasia in peripheral blood (PB) smears ( Supplementary Fig. 2c) ; white blood cell counts (WBC) were normal (Supplementary Fig. 2d ). Whereas the HSPC compartment was not altered in young, 22-week-old Rps14-haploinsufficient mice (Supplementary Fig. 2e ), long-term HSCs (LT-HSCs; lineage low c-Kit + Sca1 + CD48 − CD150 + ) and multipotent progenitor cells (MPPs; lineage low c-Kit + Sca1 + CD48 + CD150 − ) were significantly increased in frequency in the bone marrow in Rps14-haploinsufficient mice at 18 months of age (Fig. 2b) . To analyze whether the expansion of LT-HSCs might be due to exit from quiescence and enhanced LT-HSC cycling, we performed cell cycle analysis. In comparison with Mx1-Cre + controls, Rps14-haploinsufficient LT-HSCs had a significantly smaller percentage of cells in the G0 phase of cell cycle, and a significantly higher percentage of cells in the G1 and S-G2-M phases, consistent with exit from quiescence (Fig. 2c) . Because telomere length reflects the replicative history of a cell, we measured telomere length in bone marrow cells from Rps14-haploinsufficient mice and Mx1-Cre + control mice. Bone marrow cells from Rps14-haploinsufficient mice had significantly shorter telomeres than those from Mx1-Cre + control mice (Supplementary Fig. 2i ; P < 0.001).
We next examined the capacity of HSPCs to reconstitute hematopoiesis following transplantation. We transplanted cells from whole bone marrow of 18-month-old Rps14 −/+ Mx1-Cre + and Mx1-Cre +
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-/+ Mx1-Cre npg control mice into 6-to 8-week-old CD45.1 + recipient mice. Mice transplanted with Rps14 −/+ Mx1-Cre + bone marrow cells died 6-7 weeks after transplantation and had reduced hemoglobin levels and an erythroid differentiation block from the RII to RIII-IV stage, comparable to the differentiation block observed in the primary (nontransplanted) 18-month-old donor mice (Fig. 2d) . Moreover, the transplanted mice had a significant decrease in LT-HSC frequency (P < 0.05) and an increase in MPP frequency (although it was not significant) in the bone marrow ( Fig. 2e and Supplementary Fig. 2f ), but no decrease in the level of bone marrow chimerism (Supplementary Fig. 2g ).
Because Rps14 haploinsufficiency led to a significant increase in LT-HSC frequency in primary, nontransplanted mice, we examined the functional capacity of Rps14-haploinsufficient cells in a competitive repopulation assay. We transplanted Rps14 fl/+ Mx1-Cre + or Mx1-Cre + bone marrow cells in competition with an equal number of age-matched CD45.1 + competitor bone marrow cells into lethally irradiated CD45.1 + recipient mice (Fig. 2f) . Four weeks after transplantation, mice were treated with poly(I:C) to induce heterozygous Rps14 inactivation. Rps14-haploinsufficient cells outcompeted CD45.1 + competitor cells in the primary transplant, whereas Mx1-Cre + control cells had no competitive advantage (Fig. 2f) . To determine longterm repopulation potential, whole-bone marrow cells from primary recipients were transplanted into secondary recipients. In the primary recipients, the contribution of Rps14-haploinsufficient bone marrow cells was stable and showed a significantly (P < 0.05) higher chimerism than those of Mx1-Cre + controls. By 32 weeks after secondary transplantation, we observed a progressive decrease in the bone marrow chimerism of Rps14-haploinsufficient bone marrow cells to levels comparable to that of Mx1-Cre + control cells (Fig. 2f) .
Given the progressive decrease in the chimerism of Rps14-haploinsufficient cells, we evaluated the contribution of these cells to different HSPC populations 40 weeks after secondary transplantation. In the multipotent progenitor population, the frequency of Rps14-haploinsufficient cells was significantly higher than that of WT cells, whereas no differences were observed in the short-term HSC (ST-HSC; lineage low c-Kit + Sca1 + CD48 − CD150 − ) and LT-HSC populations (Fig. 2g) . In differentiated lineages, we observed significant (P < 0.05) myeloid skewing of Rps14-haploinsufficient cells, reflected by increased chimerism within the Gr1 + CD11b + granulocyte population. In contrast, chimerism within lymphoid populations did not differ significantly from that seen with Mx1-Cre + control cells (Supplementary Fig. 2h ). The chimerism of Ter119 + erythroid cells was significantly (P < 0.05) decreased in secondary recipients that were transplanted with Rps14-haploinsufficient bone marrow ( Supplementary Fig. 2h ), highlighting the distinct erythroid phenotype. Mice transplanted with equivalent numbers of Rps14-haploinsufficient and WT bone marrow cells succumbed to a severe anemia (Fig. 2h) in the setting of relatively preserved wholeblood chimerism (Fig. 2f) , suggesting that Rps14 haploinsufficiency might have cell-extrinsic effects that suppress erythropoiesis.
Taken together, these results indicate that Rps14 haploinsufficiency causes impaired terminal erythroid differentiation, an increase in HSC frequency with myeloid skewing and age-dependent loss of HSC function. Overall, this hematopoietic phenotype resembles alterations that occur during HSC aging and as a consequence of inflammation in the bone marrow [16] [17] [18] .
Ribosomal haploinsufficiency leads to global reduction in protein synthesis
Having established a mouse model that faithfully recapitulates the cardinal features of del(5q) MDS, we sought to understand how a heterozygous deletion of Rps14, which encodes a component of the 40S ribosomal subunit, alters ribosome assembly and protein synthesis. We first analyzed whether Rps14 haploinsufficiency induces quantitative changes in protein synthesis by using a fluorogenic assay (O-propargyl-puromycin; OP-puro) to visualize protein synthesis in vivo 19 . After a single intraperitoneal injection of OP-puro (50 mg/kg), we measured OP-puro incorporation as a reflection of total protein translation in a defined period of time. Overall, OP-puro incorporation was significantly (P < 0.001) reduced in Rps14 −/+ Mx1-Cre + cells relative to that in WT cells. The reduction in protein synthesis was most striking in erythroid progenitor cells ( Fig. 3a and Supplementary  Fig. 3a,b) , consistent with an erythroid differentiation block and the erythroid cell-specific requirement for high levels of ribosome biogenesis, ribosome activity and protein translation 20 .
To determine whether the Rps14 haploinsufficiency specifically affects ribosomal subunit and/or polysome formation, we performed sucrose gradient analysis of intact polysomes from FACS-purified erythroid progenitor cells (lineage low CD71 high-intermediate Ter119 + , from RII to RIII). We observed intact formation of polysome subunits ( Fig. 3b) , as expected given the rather mild, age-dependent phenotype. These findings indicate that although protein synthesis is impaired, the ribosomes that are assembled function normally. Ribosomal subunits that fail to assemble into an intact 80S ribosome may be rapidly degraded, as previously described [21] [22] [23] .
Ribosomal haploinsufficiency induces increased levels of proteins involved in innate immune function
To elucidate a mechanism for the severe erythroid differentiation defect, we performed a quantitative proteomic analysis. We purified erythroid progenitor cells (lineage low CD71 high−intermediate Ter119 + , RII-RIII) and used isobaric tags for relative and absolute quantification (iTRAQ)-based mass spectrometry (Fig. 3c) . We detected 3,524 proteins with at least two unique peptides and ratios per replicate. Of these, 26 proteins were differentially expressed (adjusted p-value of <0.05; Supplementary Table 1) . Ribosome-associated proteins had decreased expression, consistent with global reduction in protein synthesis, but intact polysome formation (Supplementary Fig. 3c ). In Rps14-haploinsufficient cells, proteins involved in innate immune system activation, including S100a8 and S100a9, were most enriched. In MDS patients, the S100A9-CD33 pathway and innate immune activation have been implicated in disease pathogenesis 24, 25 .
To validate that Rps14 haploinsufficiency induces expression of innate immune response proteins, we examined S100a8 expression by immunohistochemistry of the bone marrow of Rps14 −/+ mice and Mx1-Cre + control mice ( Fig. 4a and Supplementary Fig. 4d ). S100a8 expression was higher in bone marrow from Rps14-haploinsufficient mice than Mx1-Cre + control mice, and distinct clusters of S100A8 expressing cells were observed (Fig. 4a) . We confirmed that S100a8 mRNA and protein expression were increased in lineagenegative bone marrow cells (Fig. 4b) . To quantify S100a8 expression in defined cell populations, we simultaneously analyzed surface marker staining and intracellular S100a8 staining. In Rps14-haploinsufficient bone marrow cells, S100a8 expression was increased in the erythroid progenitor populations affected by the differentiation block (Gr1 − CD11b − CD71 high Ter119 high and Gr1 − CD11b − CD71 low Ter119 high ; RIII-RIV population) (Fig. 4c) , as well as in monocytes and macrophages (Fig. 4d,e and Supplementary Fig. 4a,b) .
Because we observed a rapidly developing anemia in chimeric mice that had been transplanted with aged Rps14-haploinsufficient whole-bone marrow cells (Fig. 2) , we also analyzed S100a8 expression npg in the bone marrow of these chimeric mice. Both monocytes and Gr1 − CD11b − CD71 low Ter119 high (RIV) erythroblasts from Rps14-haploinsufficient mice had dramatically increased expression of S100a8 as compared to those from Mx1-Cre + chimeric control mice (Supplementary Fig. 4c ; P < 0.001). This finding suggests that stress on the bone marrow, such as transplantation or aging, potentiates the expression of S100a8, with consequent effects on hematopoiesis.
The functional unit of mammalian erythropoiesis, the erythroblastic island, consists of a central macrophage that extends cytoplasmic protrusions to a ring of surrounding erythroblasts. Because we found increased S100a8 expression specifically in both erythroblasts and macrophages, we next examined expression of S100a8 and p53 in the erythroblastic island. We performed confocal imaging on cytospins of bone marrow cells from Rps14-haploinsufficient and Mx1-Cre + mice (Fig. 4d) . We found that F4/80 + macrophages from Rps14-haploinsufficient bone marrow co-expressed S100a8. In close proximity to these macrophages, we detected S100a8-expressing cells, some of which expressed p53, and the numbers of these S100a8-expressing cells was substantially increased in cells from Rps14-haploinsufficient bone marrow as compared to those from control bone marrow.
To validate that S100a8 induction leads to p53 expression in erythroid progenitor cells, we analyzed co-expression of p53 and S100a8 in erythroid progenitor cells by flow cytometry (Fig. 4e) . In the RIII population, we identified a significant induction of p53 in S100a8-expressing cells. Because p53 is a known regulator of S100a8 (refs. 26-29) , we analyzed the expression of S100a8 in Rps14-haploinsufficient cells in the presence or absence of p53, both in the steady-state condition (Supplementary Fig. 4e ) and during stress-induced erythropoiesis after treatment with phenylhydrazine (Fig. 4f) . We detected significantly decreased expression of S100a8 in Rps14 −/+ Trp53 −/− Mx1-Cre + macrophages and RIII erythroid progenitor cells, as compared to that in p53 WT control cells ( Fig. 4f and Supplementary Fig. 4e ), indicating that induction of p53 by ribosomal haploinsufficiency regulates the expression of S100a8.
Having shown that Rps14 haploinsufficiency affects not only erythroblasts but also monocytes and macrophages, we measured S100a8 mRNA expression in purified lineage low CD11b − CD71 high/ intermediate Ter119 + (RII-RIII) erythroblasts and in lineage low F4/80 + macrophages. For both cell types, Rps14-haploinsufficient cells had decreased Rps14 mRNA expression and increased S100a8 mRNA expression, as compared to that in Mx1-Cre + control cells (Supplementary Fig. 4f ; P < 0.05 F4/80 + ; P < 0.001 RII-RIII). In addition, both Rps14-haploinsufficient erythroblasts and macrophages had elevated expression of Tnfa, which encodes tumor necrosis factor (TNF)-α, a downstream target of the heterodimeric S100A8-S100A9 complex 26, 30 and a powerful repressor of erythropoiesis 25, 31 . Consistent with impaired erythroid differentiation in Rps14-haploinsufficient cells, expression of Klf1 and Gata1, which encode erythroid transcription factors, was decreased.
To investigate whether Rps14 haploinsufficiency induces an inflammatory environment in the bone marrow that represses erythropoiesis and hematopoiesis by cell-extrinsic mechanisms, we profiled the levels of 40 cytokines in bone marrow serum ( Fig. 4g and  Supplementary Fig. 4g ). We found that levels of four cytokines were significantly increased (P < 0.001) in Rps14-haploinsufficient mice, as compared to Mx1-Cre + control bone marrows-macrophage inflammatory protein (MIP)-1α (also known as Ccl3), Cxcl9, RANTES (also known as Ccl5), and interleukin (IL)-12(p40). These cytokines are predominantly expressed in activated macrophages and monocytes, have negative effects on erythropoiesis and hematopoiesis, and are 4 5 6 7 8 9 10 11 12 13 14 15 16 17 npg substantially elevated in patients with low-risk MDS [32] [33] [34] [35] . Recent studies have demonstrated that S100A8 and S100A9 are endogenous activators of Toll-like receptor 4 (TLR4) (ref. 36) . We found that Tlr4 expression was increased on both macrophages and monocytes, but not on erythroblasts, in the bone marrow of Rps14-haploinsufficient mice (Supplementary Fig. 4h ; P < 0.05), suggesting that S100a8 activates macrophages and monocytes and contributes to an inflammatory environment. We examined the roles of S100a8, Trl4 and TNF-α in causing abnormal erythropoiesis in Rps14-haploinsufficient cells using validated shRNAs (Supplementary Fig. 4i) . We transduced c-Kit + HSPCs with test and control shRNAs, induced erythroid differentiation in vitro and evaluated the effects by using flow cytometry and hemoglobinization assays ( Fig. 4h and Supplementary Fig. 4j ). Knockdown of S100a8 or Tlr4 improved erythroid differentiation and reduced p53 induction (Fig. 4i) , indicating that S100a8 and Tlr4 are central to the erythropoietic defect of Rps14 haploinsufficiency. Tnfa knockdown had a similar, although less robust, effect on erythropoiesis and had no effect on S100a8 expression (Fig. 4i,j) , suggesting a pro-inflammatory role downstream of that of S100a8.
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Mx1-Cre + -S100a8 We transduced c-Kit + HSPCs with a lentiviral vector expressing the Cas9 nuclease and a small guide RNA (sgRNA) targeting S100a8 and then analyzed erythroid differentiation in vitro. Compared to control nontargeting sgRNA (NTG-sgRNA:Cas9), CRISPR-mediated inactivation of S100a8 (using S100a8-sgRNA:Cas9) in Rps14-haploinsufficient cells rescued the terminal differentiation of hemoglobinized RIV erythroid cells (Fig. 5c) . We confirmed efficient introduction of frameshift insertion and deletion mutations in, and reduced proteinlevel expression of, S100a8 in myeloid and erythroid cells ( Fig. 5d and Supplementary Fig. 5c ).
Mx1-Cre
We next determined whether S100a8 is necessary for the erythroid-differentiation defect caused by Rps14 haploinsufficiency in vivo after phenylhydrazine-induced hemolysis (Fig. 5e-i) . We transplanted HSPCs expressing either S100a8-sgRNA:Cas9 or control NTG-sgRNA:Cas9 into lethally irradiated WT recipients, which were treated with phenylhydrazine 6 weeks after transplantation. In contrast to the control, S100a8-sgRNA:Cas9 expression in Rps14 +/− Mx1-Cre + hematopoietic cells rescued the ablation of the RIV population ( Fig. 5e and Supplementary Fig. 5e,f) , leading to a marked positive selection of Cas9:sgRNA-GFP + RIV cells (Fig. 5f) , a reduced induction of p53 and S100a8 in erythroid cells (Fig. 5g,h and Supplementary Fig. 5g ), a decreased frequency of Tlr4-expressing macrophages ( Fig. 5i and Supplementary Fig. 5d,e,g ) and a reduced induction of TNF-α (Supplementary Fig. 5h ). These data demonstrate the functional requirement for S100a8 in the induction of a p53-dependent erythroid-differentiation defect and an increase in the frequency of Tlr4-expressing macrophages in the setting of Rps14 haploinsufficiency.
To examine cell-intrinsic effects of S100a8 in Rps14-haploinsufficient cells, we purified RII erythroblasts and measured the effect of S100a8 inactivation on their terminal differentiation, in the absence of myeloid cells (Supplementary Fig. 5i ). Purified Rps14-haploinsufficient RII progenitor cells expressing a control sgRNA did not terminally differentiate and underwent apoptosis, whereas those expressing S100a8-sgRNA:Cas9 differentiated into hemoglobinized, terminally differentiated erythroid cells. These data indicate that S100a8 directly affects erythroid progenitor cells by intrinsic mechanisms.
Next, to examine potential cell-extrinsic effects of S100a8, we analyzed S100a8 and p53 induction in competitive transplant studies, in both WT competitor cells (CD45.1 + ) and in Rps14 +/− Mx1-Cre + or Mx1-Cre + (CD45.2 + ) cells (Supplementary Fig. 5j) . Induction of S100a8 expression was restricted to CD45.2 + Rps14-haploinsufficient cells as compared to WT competitor (CD45.1 + ) (P < 0.001) or Mx1-Cre + cells (P < 0.05). In contrast, induction of p53 expression occurred in CD45.1 + competitor cells only after they were mixed with CD45.2 + Rps14-haploinsufficient cells and not in the presence of Mx1-Cre + cells (P < 0.05). This finding is consistent with the idea that increased S100a8 expression in Rps14-haploinsufficient cells exerts a pro-apoptotic effect on WT cells that may drive progressive anemia in a cell-extrinsic fashion, even in the setting of preserved whole-bone marrow chimerism. Taken together, these data demonstrate that S100a8 exerts both cellintrinsic and cell-extrinsic effects on erythropoiesis.
The frequency of S100A8 + cells in del(5q) MDS human bone marrow positively correlates with disease severity To examine whether ribosomal haploinsufficiency leads to activation of S100A8 in individuals with del(5q) MDS, we performed immunofluorescence for S100A8 and the erythroid marker glycophorin A (GlyA) in bone marrow biopsies from non-MDS control individuals (normal) and MDS patients with and without the del(5q) lesion (Fig. 6, Supplementary Fig. 6a,b and Supplementary Table 2) . In biopsies from normal individuals (control), rare S100A8-expressing cells were interspersed in the hematopoietic marrow. In biopsies from individuals with del(5q) MDS, S100A8 + cells were positioned in the marrow in groups of >5 cells. The frequency of S100A8-expressing nucleated cells was substantially increased in bone marrow biopsies from subjects with del(5q) MDS as compared to those from normal individuals (Supplementary Fig. 6b ). GlyA + early erythroid progenitor cells occasionally co-expressed S100A8 (Fig. 6a, inset) , similarly to what was observed in the Rps14-haploinsufficient mouse model. In aggregate, these data indicate that impaired erythropoiesis in the bone marrow of patients with del(5q) MDS is associated with aberrant expression of S100A8.
DISCUSSION
Anemia is the most common hematologic manifestation of MDS, particularly in patients with del(5q) MDS. In a newly generated conditional-knockout mouse model of Rps14, we found that Rps14 haploinsufficiency is sufficient to cause a p53-dependent erythroiddifferentiation defect, associated with apoptosis, that results in agedependent progressive anemia, megakaryocyte dysplasia and loss of HSC quiescence. In an unbiased proteomic analysis, we identified a link between Rps14 haploinsufficiency and induction of the dangerassociated molecular pattern (DAMP) heterodimer S100a8-S100a9 in monocytes, macrophages and erythroblasts. Our studies link the p53-dependent erythroid-differentiation defect to induction of S100a8 and an inflammatory environment to which both monocytes and macrophages contribute, and we demonstrate that ribosomal haploinsufficiency exerts both cell-intrinsic and cell-extrinsic effects on erythropoiesis and hematopoiesis. Figure 6 S100A8 + cell frequency is increased in bone marrow from individuals with del(5q) MDS. (a) Representative images of immunofluorescence staining for glycophorin A (GlyA, magenta), S100A8 (green) and DAPI (blue, nuclear stain) in healthy individuals (normal; n = 15), patients with del(5q) MDS (n = 21) and subjects with normal-karyotype MDS (non-del(5q) MDS; n = 9). The inset depicts cells that co-express S100A8 and GlyA. Scale bars, 100 µm and 10 µm (inset). Micrographs for all individuals are shown in Supplementary Figure 6. (b) Quantification of S100A8 + cells as a percentage of DAPI + , nucleated bone marrow cells (healthy (normal) individuals, n = 15; patients with del(5q) MDS, n = 21; subjects with normal-karyotype MDS (non-del(5q) MDS), n = 9). Data are mean ± s.d. **P < 0.001; by unpaired two-sided t-test.
npg S100A8-S100A9 expression is induced during inflammatory processes including infection, autoimmunity, and cancer 26, 36, 37 . In addition to granuloyctes and macrophages, which produce these proteins under steady-state conditions, other cell types induce S100A8-S100A9 expression in response to stress 30 . As a consequence of Rps14 haploinsufficiency, S100a8 expression was induced in both CD11b + monocytes and F4/80 + macrophages, as well as in latestage erythroblasts, and induction of S100a8 in erythroblasts was associated with increased p53 expression. Our data indicate that disruption of regulatory mechanisms in the erythroblastic island, in which erythroid progenitor cells interact with a central macrophage, contributes to the erythroid-differentiation defects observed in the bone marrow of Rps14-haploinsufficient mice. S100A9 activation has been described in MDS patient samples 24, 38 , and the S100A9-CD33 pathway in myeloid-derived suppressor cells (MDSCs) perturbs hematopoiesis 24 . On the basis of our data, we posit that the S100A8 and S100A9 proteins-which are induced as a stress response by ribosomal haploinsufficiency in monocytes, macrophages and erythroblasts-contribute to the MDS phenotype.
The S100A8-S100A9 heterodimer, an endogenous TLR4 ligand, acts upstream of TNF-α and promotes the activation of the transcription factor NF-κB and the secretion of pro-inflammatory cytokines 37 . Consistent with this previous work, our data demonstrate that in the setting of Rps14 haploinsufficiency, S100a8 acts upstream of Tlr4 and TNF-α in contributing to the erythroid-differentiation defect. RPS14 and microRNA 145 (MIR145) are always co-deleted in the 5q-syndrome, and both converge mechanistically on TLR4 signaling 25, [39] [40] [41] [42] [43] , highlighting potential cooperative and additive effects of genes that affect the same downstream pathways on the 5q-syndrome (Supplementary Fig. 7) . S100 proteins participate in an autoregulatory feedback loop with p53, serving both as upstream drivers of Trp53 gene transcription and as direct downstream p53 transcriptional targets [26] [27] [28] [29] . Consistent with these reports, we found that p53 is required for induction of S100a8 expression in Rps14-deleted cells and that adding recombinant S100a8 is sufficient to induce p53 activity in erythroid progenitor cells, leading to a block in terminal erythroid differentiation.
Specific cytokines are elevated in the serum of individuals with MDS 33 , and these inflammatory signals can alter the proliferation and apoptosis of MDS HSPCs 44, 45 . Indeed, chronic immune stimulation, coupled with senescence-dependent changes 46 in both HSPCs and the bone marrow microenvironment 47 , may be central to the pathogenesis of MDS 25, 40, 48 . Our analysis of Rps14-deleted HSCs suggests that inflammatory cues that are induced by Rps14 haploinsufficiency impact HSC aging and quiescence 17, 18, 42, 49 . In patients with chronic inflammation, cytokines in the bone marrow have been associated with inhibition of erythropoiesis 50 . In particular, TNF-α expression has been implicated in the erythroid defects observed in patients with DBA 31 , and it is upregulated in the bone marrow serum of patients with MDS 51, 52 . Moreover, TNF receptor-associated factor 6 (TRAF6) activation, a process targeted by miR-145 and miR-146a, induces myelodysplasia in a mouse model 25 .
Our data link haploinsufficiency of a ribosomal gene, Rps14, with the activation of S100A8-S100A9 and other inflammatory molecules and the inhibition of erythropoiesis. An intervention that blocks this process, potentially through pharmacologic targeting of S100A8-S100A9, could improve red blood cell production in individuals with del(5q) MDS. These findings underscore a molecular link between the genetic abnormalities in patients with MDS, activation of the innate immune system and the ineffective hematopoiesis that characterizes the disease.
METHODS
Methods and any associated references are available in the online version of the paper.
ONLINE METHODS
Generation of Rps14 conditional-knockout mice and mouse experiments.
The Rps14 target region is 2.12 kb and includes exons 2-4. Briefly, a 10.64-kb region that was used to construct the targeting vector was first subcloned from a positively identified C57BL/6 BAC (bacterial artificial chromosome) clone (RP23: 205B18). The region was designed such that the 5′ homology arm extends about 5.76 kb 5′ to the single LoxP site. The 3′ homology arm ends 3′ to the loxP-and FRT-flanked neomycin (Neo) cassette and is 2.76 kb long. The loxP-and FRT-flanked Neo cassette was inserted 255 bp downstream of exon 4. The single loxP site, containing engineered ApaLI and Bcl I sites for Southern blot analysis, was inserted 379 bp upstream of exon 2. The targeting vector was confirmed by restriction site analysis after each modification step. P6 and T7 primers anneal to the backbone vector sequence and were used to read into the 5′ and 3′ ends of the BAC subclone. N1 and N2 primers anneal to the 5′ and 3′ ends of the LoxP-FRT-Neo cassette and were used to sequence the short homology arm (SA) and long homology arm (LA), respectively. The BAC was subcloned into a ~2.4-kb backbone vector (pSP72, Promega) containing an ampicillin selection cassette for retransformation of the construct before electroporation. A pGK-gb2 loxP-FRT-Neo cassette was inserted into the gene. The targeting construct was linearized using NotI before electroporation into embryonic stem (ES) cells. The total size of the targeting construct (including vector backbone and Neo cassette) is 14.74 kb. Targeted iTL IC1 (C57BL/6N) embryonic stem cells were microinjected into BALB/c blastocysts. Resulting chimeras with a high percentage of black coat color were mated to wild-type C57BL/6N mice to generate F1 heterozygous offspring. Tail DNA was analyzed from pups with black coat color. PCR was performed to detect the presence of the distal LoxP site using 'LEVI 3′' (5′-GTGATCTCAACGCAGGTGTGTAGC-3′) and 'SDL2' (5′-TAACAGCATGGAAGTCGGGTCTCA-3′) primers. This reaction amplifies a wild-type product 474 bp in size. The presence of a second PCR product 73 bp larger in size than the wild-type product indicates the presence of a distal LoxP site.
Chimeric mice were generated by standard methods. The Neo cassette was deleted by crossing the mice with transgenic FLP1 recombinase mice purchased from Jackson Lab (Strain:B6.Cg-Tg(ACTFLPe)9205Dym/J). Chimeric mice were genotyped by PCR with primers reverse (5′-GTGATCTCAACGCAGGTGTGT AGC-3′) and forward (5′-TAACAGCATGGAAGTCGGGTCTCA-3′) using the following parameters: 95 °C for 3 min, followed by 35 cycles of 95 °C for 30 s, 60 °C for 1 min and 72 °C for 1 min. Following confirmation of germline transmission, mice were crossed with the Mx1-Cre mouse strain (Jackson: 002527). To excise Rps14 exon 2-4, 6-to 8-week-old Rps14 conditional mice (and Mx1-Cre + mice as controls) were given three rounds of 200 µg poly(I:C) (GE Healthcare Life Sciences) using intraperitoneal injections. Excision after Cre recombination was confirmed by PCR with primers to detect a floxed portion of the construct (Ndel 2: 5′-GTATCTCCAATGGTCAGCAATCACGG-3′ and LEVI: 5′-GTGATCTCAACGCAGGTGTGTAGC-3′). The sizes of the PCR products from the floxed and WT alleles are 511 and 623 bp, respectively. For qRT-PCR, the Rps14-specific Taqman probe mCG6028 was used in a Taqman expression Assay (Assay ID Mm00849906_g1; Life Technologies # 4331182). Rps14-haploinsufficient mice were further bred to p53-null mice (Jackson stock number 00813). Animals were monitored two to three times a week for the presence of disease by general inspection and palpation. Peripheral blood was collected from the retro-orbital cavity using an EDTA-treated glass capillary and automated total and differential blood cell counts were determined using a Hemavet 950 instrument (Drew Scientific). Following sacrifice, mice were examined for the presence of abnormalities, and organs were collected for further cell and histopathological analysis. Due to the experimental design, the genotypes of the mice could not be blinded or randomized. The group size was chosen based on our experience with conditional mouse knockout models of genes on 5q in order to detect a disease-typical fold change as significant 53 . All groups of mice (experimental and control mice) were age-and sex-matched. Mouse experiments were performed according to an Institutional Animal Care and Use Committee (IACUC)-approved protocol at Children's Hospital Boston.
Flow cytometry and cell isolation. Bone marrow cells were isolated by flushing and crushing the pelvis, hind leg bones and vertebrae, using a mortar and pestle, in PBS (GIBCO) supplemented with 2% heat-inactivated FBS (FBS) and penicillin-streptomycin (GIBCO). Whole bone marrow was lysed on ice with red blood cell (RBC) lysis solution (Invitrogen/Life Technologies) and washed in PBS (GIBCO) with 2% FBS. Single-cell suspensions of spleen were prepared by pressing tissue through a 70-µm cell strainer followed by red blood cell lysis. Cells were labeled with monoclonal antibodies in 2% FBS-PBS for 30 min on ice. For flow cytometric analysis and isolation of specific hematopoietic progenitors, cells were incubated with combinations of antibodies to the following cell surface markers (conjugated to FITC, phycoerythrin (PE), allophycocyanin (APC), PercP-Cy5.5, APC-Cy7 (APC-efluor780), Pe-Cy7, Alexa Fluor 700, Pacific blue (efluor450) or biotin): CD3 (17A2), CD5 (53-7. 3), CD11b (M1/70), Gr1 (RB6-8C5), B220 (RA3-6B2), Ter119 (TER119), CD71 (C2), c-Kit (2B8), Sca1 (D7), CD34 (RSM34), CD16/32 (93), CD150 (TC15-12F12.2), CD48 (HM48-1), CD45.1 (A20), CD45.2 (104). For sorting of lineage-negative cells, lineage markers included CD3, CD5, CD11b, Gr1 and Ter119. For sorting of erythroid progenitor cells, the lineage cocktail did not include Ter119. All reagents were acquired from BD Biosciences, eBiosciences, or BioLegend. To increase the sorting efficiency, whole-bone marrow samples were either lineage-depleted or c-Kit-enriched using paramagnetic microbeads and an autoMACS magnetic separator (Miltenyi Biotec). Cell sorting was performed on a FACSAria flow cytometer (BD Biosciences); data acquisition was performed on an LSR II or Canto II instrument (BD Biosciences). Data were analyzed by FlowJo (Tree Star) software.
Long-term competitive repopulation assays. In competitive bone marrow transplantation studies, 2 × 10 6 freshly isolated bone marrow cells were transplanted in competition with 2 × 10 6 freshly isolated CD45.1 + bone marrow cells, via tail vein injection, into female lethally irradiated (10.5 Gy) 6-to 8-week-old CD45.1 + recipient mice. Donor cell chimerism was determined in the peripheral blood 4 weeks after transplantation before the excision of Rps14 was induced by poly(I:C) injection (week 0) as well as every 4-8 weeks. Red blood cells were lysed (Invitrogen/Life Technologies) and the remaining cells were stained with antibodies against CD45.2, CD45.1, Gr1, CD11b, CD3, and CD19 (eBio1D3) to assess donor cell engraftment. For secondary transplants, 5 × 10 6 bone marrow cells collected from primary recipients were transplanted into lethally irradiated CD45.1 + recipient mice.
In vivo measurement of protein synthesis. One hundred microliters of a 20 mM solution of O-propargyl-puromycin (OP-puro; Life Technologies) was injected intraperitoneally; mice injected with PBS were used as controls. Bone marrow and spleen were harvested after 1 hour and then kept on ice. 3 × 10 6 cells were stained with antibodies against cell surface markers, fixed in 1% paraformaldehyde, and permeabilized in PBS with 3% FBS and 0.1% saponin. An azidealkyne cyclo-addition was performed using the Click-iT Cell Reaction Buffer Kit (Life Technologies) and an azide-derived dye (conjugated to Alexa Fluor 488; Life Technologies) at 5 µM final concentration for 30 min. Cells were washed twice again and then analyzed by flow cytometry. 'Relative rates of protein synthesis' were calculated by normalizing OP-Puro signals to whole bone marrow after subtracting background auto-fluorescence, as described by Singer et al. 19 .
Methylcellulose assays. 48 h after viral transduction, 15,000 c-Kit + cells were sorted and plated in semisolid methylcellulose culture medium (M3434, StemCell Technologies) and incubated at 37 °C in a humidified atmosphere. Colony formation was assessed 7 d after plating.
shRNA and sgRNA:CRISPR-Cas9 vector construction, virus production and transduction. Lentivirally expressed shRNAs in the pLKO.1 backbone vector (puromycin resistance) were obtained from the RNAi Consortium at the Broad Institute. The S100A8-specific guide RNA (gRNA; forward 5′-CACCGAATTGTG GTAGACATCAATG-3′; reverse 5′-AAACCATTGATGTCTACCACAATTC-3′) was cloned into pL-CRISPR.EFS.GFP (http://www.addgene.org/57827) using BsmBI restriction digestion. Lentiviral particles were produced by transient transfection of 293T cells with lentivirus plasmid together with pSPAX and VSVG packaging plasmids using TransIT-LT (Mirus). Lentiviral particles were concentrated using ultracentrifugation. c-Kit + or lineage-negative cells were cultured in StemSpan SFEM (StemCell Technologies) supplemented with npg 50 ng/ml murine thrombopoietin (ThPO) and 50 ng murine stem cell factor (SCF) (both Peprotech) for 24 h and then transduced with concentrated lentiviral supernatant in the presence of 2 µg/ml Polybrene using spin-infection for 90 min at 2,200 r.p.m. at 37 °C.
Sequencing analysis of CRISPR variants.
To assess the proportion and diversity of CRISPR variants, we performed PCR-amplicon deep sequencing of bulk genomic DNA at the S100a8 sgRNA target site (chr3:90669574-90669596; mm9 genome build) using the primers S100a8-g1-F: 5′-GGACACTCAGTAGTGACCATTT-3′ and S100a8-g1-R: 5′-GAGTAACTGCAGCTCCCATC-3′. After addition of sample indexes and sequencing adaptors, the product was subjected to 150-nt paired-end sequencing on an Illumina MiSeq instrument, producing approximately 100,000 reads per sample. Reads were then aligned to the genomic reference and grouped according to specific insertion and deletion sequences.
In vitro erythroid differentiation. Total bone marrow cells were labeled with biotin-conjugated anti-lineage antibodies, consisting of anti-CD3e, anti-CD11b, anti-CD45R-B220, anti-Ly6G-Ly6C and anti-TER-119 (BD Pharmingen, San Diego, CA) and purified using anti-biotin beads and negative selection on an autoMACS instrument (Miltenyi Biotec). Purified cells were then seeded in fibronectin-coated (2 µg/cm 2 ) tissue culture-treated polystyrene wells (BD Discovery Labware, Bedford, MA) at a cell density of 1 × 10 5 per ml. Erythroid differentiation was carried out according to modified, published protocols 54 . The erythropoietic medium consisted of Iscove's modified Dulbecco's medium (IMDM; Gibco) supplemented with erythropoietin (EPO) at 10 units/ml, 10 ng/ml SCF (Peprotech), 10 µM dexamethasone (Sigma), 15% FBS, 1% detoxified BSA, 200 µg/ml holotransferrin (Sigma, St. Louis, MO), 10 µg/ml recombinant human insulin (Sigma), 2 mM l-glutamine, 10 −4 M β-mercaptoethanol and penicillin-streptomycin. After 48 h the medium was replaced by maintenance medium consisting of IMDM with 20% FBS, 2 mM l-glutamine and 10 −4 M β-mercaptoethanol. Recombinant S100a8 (mouse, Abnova P4345) protein was used where indicated, at a concentration of 1 µg/ml. Phenylhydrazine treatment. Phenylhydrazine was purchased from Sigma and injected subcutaneously at two consecutive days (days 0 and 1) at a dose of 35 or 25 mg/kg, as previously described 55 . Peripheral blood was collected 4 d before the start of treatment and at days 3, 6 and 9 after initial injection. Phenylhydrazine treatment experiments were carried out in 8-to 12-week-old mice. All groups of mice (experimental and control mice) were age-and sex-matched.
Polysome profiling. For polysome profiling of primary erythroid progenitor cells, whole bone marrow was lineage-depleted (CD3, CD5, B220, Gr1, and CD11b) using microbeads and the autoMACS instrument as described above and stained for Ter119 and CD71. Erythroid progenitor cells (lineage − CD71 high Ter119 intermediate/high ) were sort-purified in 100% FCS and cultured for 1 h in IMDM with 20% FCS and 2 mM l-glutamine at 37 °C under humidified conditions. Cells (approximately 3 × 10 6 ) were then harvested, spun down and incubated with 100 µg/ml cycloheximide for 10 min at 37 °C, washed with ice-cold PBS containing 100 µg/ml cycloheximide and lysed in 300 µl of a solution containing 5 mM Tris (pH 7.4), 2.5 mM MgCl 2 and 1.5 mM KCl. Gradients were poured using a Biocomp Gradient Station. Polysomes were separated on a 10-50% linear sucrose gradient containing 20 mM HEPES-KOH (pH 7.4), 5 mM MgCl 2 , 100 mM KCl, 2 mM DTT and 100 µg/ml cycloheximide and centrifuged at 36,000 r.p.m. for 2 h in a Beckman Coulter L8-M centrifuge with a SW40Ti rotor. Gradients were fractionated using a Gilson FC-203B fractionator. Absorbance at 254 nm was used to visualize the gradients using a BioRad EM-1 Econo UV monitor.
iTRAQ labeling of peptides and basic reversed-phase (brp) fractionation. 20 million RII and RIII erythroblasts (four biological replicates per one technical or process process replicate) were sort-purified and resuspended in 500 µl lysis buffer (8 M urea, 50 mM Tris HCl, 1 mM EDTA, 75 mM NaCl, aprotinin, leupeptin, PMSF, NaF, proteinase inhibitor cocktails 2 and 3; all Sigma), vortexed on ice and spun at 20,000g for 10 min at 4 °C. 300 µg protein of each sample was reduced (2 µl 500 mM DTT, 30 min, RT), alkylated (4 µl 500 mM iodoacetic acid, 45 min, dark) and digested using 2 µg of sequencing-grade trypsin overnight with shaking at room temperature (Supplementary Table 3) . The samples were then quenched and desalted on 10 mg SepPak columns. Desalted peptides were labeled with iTRAQ reagents according to the manufacturer's instructions (AB Sciex, Foster City, CA). Peptides were dissolved in 30 µl 0.5 M TEAB pH 8.5 solution (Sigma-Aldrich) and labeling reagent was added in 70 µl of ethanol. After a 1-h incubation, the reaction was stopped with 50 mM Tris-HCl pH 7.5. Differentially labeled peptides were mixed and subsequently desalted on a 30 mg SepPak column. Basic reversed-phase fractionation and subsequent concatenation of the differentially labeled and combined peptides was performed as described by Mertins et al. 56 with the following amendment: the Zorbax 300-Å extended C18 column used was 2.1 × 150 mm with a 3.5-µm bead size (Agilent).
Mass spectrometry analysis. Reconstituted peptides were separated on an online nanoflow EASY-nLC 1000 UHPLC system (Thermo Fisher Scientific) and analyzed on a benchtop Orbitrap Q Exactive mass spectrometer (Thermo Fisher Scientific). The peptide samples were injected onto a capillary column (Picofrit with 10-µm tip opening and 75-µm diameter, New Objective, PF360-75-10-N-5) packed in-house with 20 cm C18 silica material (1.9-µm ReproSil-Pur C18-AQ medium, Dr. Maisch GmbH, r119.aq). The UHPLC setup was connected with a custom-fit microadapting tee (360 µm, IDEX Health & Science, UH-753), and capillary columns were heated to 50 °C in column heater sleeves (Phoenix-ST) to reduce backpressure during ultra-high pressure liquid chromatography (UHPLC) separation. Injected peptides were separated at a flow rate of 200 nl/min with a linear 80-min gradient from 100% solvent A (3% acetonitrile, 0.1% formic acid) to 30% solvent B (90% acetonitrile, 0.1% formic acid), followed by a linear 6-min gradient from 30% solvent B to 90% solvent B. Each sample was run for 120 min, including sample loading and column equilibration times. The Q Exactive instrument was operated in the data-dependent mode acquiring higherenergy collisional dissociation tandem mass spectrometry (HCD MS/MS) scans (R = 17,500) after each MS1 scan (R = 70,000) on the 12 most abundant ions using an MS1 ion target of 3 × 10 6 ions and an MS2 target of 5 × 10 4 ions. The maximum ion time used for the MS/MS scans was 120 ms; the HCD-normalized collision energy was set to 27; the dynamic exclusion time was set to 20 s, and the peptide-match and isotope-exclusion functions were enabled.
Quantification and identification of peptides and proteins. All mass spectra were processed using the Spectrum Mill software package v4.2 prerelease (Agilent Technologies), which includes modules developed by us for iTRAQ-based quantification. Precursor ion quantification was done using extracted ion chromatograms (XIC's) for each precursor ion. The peak area for the XIC of each precursor ion subjected to MS/MS was calculated automatically by the Spectrum Mill software in the intervening high-resolution MS1 scans of the liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) runs using narrow windows around each individual member of the isotope cluster. Peak widths in both the time and m/z domains were dynamically determined based on MS-scan resolution, precursor charge and m/z, subject to quality metrics on the relative distribution of the peaks in the isotope cluster versus theoretical distribution. Similar MS/MS spectra acquired on the same precursor m/z in the same dissociation mode within ± 60 s were merged. MS/MS spectra with precursor charge >7 and poor quality MS/MS spectra, which failed the quality filter by not having a sequence tag length >1 (i.e., a minimum of three masses separated by the in-chain mass of an amino acid) were excluded from searching. For peptide identification, MS/MS spectra were searched against the mouse Uniprot database to which a set of common laboratory contaminant proteins was appended. Search parameters included: ESI-QEXACTIVE-HCD scoring parameters, trypsin enzyme specificity with a maximum of two missed cleavages, 40% minimum matched peak intensity, ±20 p.p.m. precursormass tolerance, ±20 p.p.m. product-mass tolerance, and carbamidomethylation of cysteines, iTRAQ labeling of lysines and peptide N termini as fixed modifications. Allowed variable modifications were oxidation of methionine, N-terminal acetylation, pyroglutamic acid (N-termQ), deamidated (N), pyrocarbamidomethyl, Cys (N-termC), with a precursor MH + shift range of −18 Da to 64 Da. Identities interpreted for individual spectra were automatically designated as valid by optimizing score and delta rank1-rank2 score thresholds separately for each precursor charge state in each LC-MS/MS, while allowing a maximum target decoy-based false-discovery rate (FDR) of 1.0% at the spectrum level. In calculating scores at the protein level and reporting the identified proteins, redundancy was addressed in the following manner: the protein score is the sum of the scores of distinct peptides. A distinct peptide is the single highest-scoring instance of a peptide detected through an MS/MS spectrum. MS/MS spectra for a particular peptide may have been recorded multiple times (i.e., as different precursor-charge states, isolated from adjacent brp fractions, and modified by oxidation of methionine), but which are still counted as a single distinct peptide. When a peptide sequence >8 residues long is contained in multiple protein entries in the sequence database, the proteins are grouped together and the highest-scoring one and its accession number are reported. In some cases in which the protein sequences are grouped in this manner, there are distinct peptides which uniquely represent a lower-scoring member of the group (isoforms or family members). Each of these instances spawns a subgroup, in which case multiple subgroups are reported and counted toward the total number of proteins. iTRAQ ratios were obtained from the protein-comparisons export table in Spectrum Mill. To obtain iTRAQ protein ratios, the median was calculated over all distinct peptides assigned to a protein subgroup in each replicate 57 . To assign differentially expressed proteins, we used the Limma package in the R environment to calculate moderated t-test P, as described previously. We also added Blandt-Altman testing to filter out proteins for which the confidence interval for reproducibility was below 95%. Normalized iTRAQ ratios for the two biological replicates were filtered to retain only those deemed reproducible. Reproducible replicates were then subjected to a moderated t-test to assess statistical significance. This statistic is similar to the ordinary t-statistic, with the exception that standard errors are calculated using an empirical Bayes method using information across all proteins, thereby making inference about each individual protein more robust. The nominal P values arising from the moderated t-statistic were corrected for multipletesting by controlling the false-discovery rate (FDR), as proposed by Benjamini and Hochberg. Proteins with an FDR-adjusted P < 0.01 were deemed to be reproducibly regulated. Statistical significance was assessed using only reproducible data points.
